{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:51:28Z","timestamp":1786985488237,"version":"build-2736575974"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.brainres.2025.149738","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:42:52Z","timestamp":1748518972000},"page":"149738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Parkinson\u2019s disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics"],"prefix":"10.1016","volume":"1862","author":[{"given":"Behina","family":"Foroozanmehr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Hemmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Yaribeygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Karav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Jamialahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2025.149738_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114849","article-title":"Novel therapeutic interventions for combating Parkinson\u2019s disease and prospects of Nose-to-Brain drug delivery","volume":"195","author":"Ahmad","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.brainres.2025.149738_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104707","article-title":"Insulin signaling pathway and related molecules: role in neurodegeneration and Alzheimer's disease","volume":"135","author":"Akhtar","year":"2020","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.brainres.2025.149738_b0015","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/35094583","article-title":"Cytokines and acute neurodegeneration","volume":"2","author":"Allan","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.brainres.2025.149738_b0020","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.brainres.2025.149738_b0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","article-title":"Insulin resistance and Parkinson\u2019s disease: A new target for disease modification?","volume":"145\u2013146","author":"Athauda","year":"2016","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.brainres.2025.149738_b0030","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.brainres.2025.149738_b0035","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/mds.29122","article-title":"The impact of type 2 diabetes in Parkinson's disease","volume":"37","author":"Athauda","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2025.149738_b0040","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/mds.29122","article-title":"The impact of type 2 diabetes in Parkinson's disease","volume":"37","author":"Athauda","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2025.149738_b0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","article-title":"Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study","volume":"141","author":"Attems","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.brainres.2025.149738_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.dscb.2024.100163","article-title":"Novel approaches targeting \u03b1-Synuclein for Parkinson's Disease: current progress and future directions for the disease-modifying therapies","volume":"16","author":"Baggett","year":"2024","journal-title":"Brain Disorders."},{"key":"10.1016\/j.brainres.2025.149738_b0055","first-page":"27","volume":"27","author":"Balestrino","year":"2020","journal-title":"Parkinson Disease. Europe. J. Neurol."},{"key":"10.1016\/j.brainres.2025.149738_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.02.005","article-title":"Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?","volume":"118","author":"Bassil","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.brainres.2025.149738_b0065","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s00125-021-05415-5","article-title":"Defining the underlying defect in insulin action in type 2 diabetes","volume":"64","author":"Batista","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.brainres.2025.149738_b0070","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.parkreldis.2014.10.008","article-title":"Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease","volume":"20","author":"Bohnen","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.brainres.2025.149738_b0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-clinpsy-050212-185608","article-title":"Network analysis: an integrative approach to the structure of psychopathology","volume":"9","author":"Borsboom","year":"2013","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.brainres.2025.149738_b0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2011.12.008","article-title":"Dementia is associated with insulin resistance in patients with Parkinson's disease","volume":"315","author":"Bosco","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0085","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-002-1301-4","article-title":"Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)","volume":"249","author":"Braak","year":"2002","journal-title":"J. Neurol."},{"key":"10.1016\/j.brainres.2025.149738_b0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fnmol.2012.00013","article-title":"A pivotal role of GSK-3 in synaptic plasticity","volume":"5","author":"Bradley","year":"2012","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.brainres.2025.149738_b0095","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/diabetes.50.2007.S140","article-title":"IRS proteins and beta-cell function","volume":"50","author":"Burks","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.brainres.2025.149738_b0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/153537020122600103","article-title":"Insulin resistance: cellular and clinical concepts","volume":"226","author":"Cefalu","year":"2001","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.brainres.2025.149738_b0105","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1212\/WNL.0b013e3182553cc9","article-title":"Clinical features of Parkinson disease when onset of diabetes came first: a case-control study","volume":"78","author":"Cereda","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2025.149738_b0110","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/mds.28551","article-title":"Type 2 diabetes as a determinant of Parkinson's disease risk and progression","volume":"36","author":"Chohan","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2025.149738_b0115","unstructured":"Choi, I.Y., Lee, J.S., Kim, J.K., Park, Y.J., Jung, S.Y., Kim, Y.H., Kwon, S.C., 2017. Potent body weight loss and efficacy in a NASH animal model by a novel long-acting GLP-1\/Glucagon\/GIP triple-agonist (HM15211). American Diabetes Association\u2019s 77th Scientific Session."},{"key":"10.1016\/j.brainres.2025.149738_b0120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000325028","article-title":"Direct interaction of \u03b1-synuclein and AKT regulates IGF-1 signaling: implication of Parkinson disease","volume":"19","author":"Chung","year":"2011","journal-title":"Neurosignals"},{"key":"10.1016\/j.brainres.2025.149738_b0125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.parkreldis.2018.08.023","article-title":"Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease","volume":"64","author":"Chung","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.brainres.2025.149738_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/biom11040612","article-title":"Treatment options for motor and non-motor symptoms of Parkinson's disease","volume":"11","author":"Church","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.brainres.2025.149738_b0135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1474-4422(04)00681-7","article-title":"Insulin and neurodegenerative disease: shared and specific mechanisms","volume":"3","author":"Craft","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainres.2025.149738_b0140","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainres.2025.149738_b0145","unstructured":"De Meyts, P., 2016. The insulin receptor and its signal transduction network. Endotext [Internet]."},{"key":"10.1016\/j.brainres.2025.149738_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.brainres.2025.149738_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179583","article-title":"Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ar.1092070108","article-title":"Insulin- and glucagonlike peptides in the brain","volume":"207","author":"Dorn","year":"1983","journal-title":"Anat. Rec."},{"key":"10.1016\/j.brainres.2025.149738_b0165","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1101\/lm.88005","article-title":"Insulin receptor signaling in long-term memory consolidation following spatial learning","volume":"12","author":"Dou","year":"2005","journal-title":"Learn. Mem."},{"key":"10.1016\/j.brainres.2025.149738_b0170","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.brainres.2025.149738_b0175","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.brainres.2025.149738_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117540","article-title":"Insulin mediated novel therapies for the treatment of Alzheimer's disease","volume":"249","author":"Dubey","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0185","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1096\/fj.08-120410","article-title":"\u03b1-Synuclein contributes to GSK-3\u03b2-catalyzed Tau phosphorylation in Parkinson\u2019s disease models","volume":"23","author":"Duka","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.brainres.2025.149738_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103021","article-title":"GLP-1 receptor agonists beyond diabetes management","volume":"78","author":"eClinicalMedicine","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.brainres.2025.149738_b0195","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","article-title":"GLP-1\u2019s role in neuroprotection: a systematic review","volume":"33","author":"Erbil","year":"2019","journal-title":"Brain Inj."},{"key":"10.1016\/j.brainres.2025.149738_b0200","first-page":"65","article-title":"Apoptosis and its role in Parkinson\u2019s disease","author":"Erekat","year":"2018","journal-title":"Exon Publications."},{"key":"10.1016\/j.brainres.2025.149738_b0205","unstructured":"Ewa, \u015a., Justyna, S., Adam, W., Janusz, S., J\u00f3zef, D., Agnieszka, \u015a., 2018. Role of PI3K\/AKT Pathway in Insulin-Mediated Glucose Uptake. In Blood Glucose Levels. Vol., S. Leszek, ed.^eds. IntechOpen, Rijeka, pp. Ch. 3."},{"key":"10.1016\/j.brainres.2025.149738_b0210","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.140.3.6578","article-title":"Cloning, tissue expression, and chromosomal location of the mouse insulin receptor substrate 4 gene","volume":"140","author":"Fantin","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.brainres.2025.149738_b0215","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrn3209","article-title":"The many faces of insulin-like peptide signalling in the brain","volume":"13","author":"Fernandez","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.brainres.2025.149738_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108277","article-title":"Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives","volume":"239","author":"Ferrari","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.brainres.2025.149738_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134567","article-title":"Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson's Disease","volume":"714","author":"Fine","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.brainres.2025.149738_b0230","article-title":"Insulin and its key role for mitochondrial function\/dysfunction and quality control: a shared link between dysmetabolism and neurodegeneration","volume":"11","author":"Galizzi","year":"2022","journal-title":"Biology (basel)"},{"key":"10.1016\/j.brainres.2025.149738_b0235","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3390\/biology11060943","article-title":"Insulin and its key role for mitochondrial function\/dysfunction and quality control: a shared link between dysmetabolism and neurodegeneration","volume":"11","author":"Galizzi","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.brainres.2025.149738_b0240","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.628541","article-title":"Role of mTOR-regulated autophagy in synaptic plasticity related proteins downregulation and the reference memory deficits induced by anesthesia\/surgery in aged mice","volume":"13","author":"Gao","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.brainres.2025.149738_b0245","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1212\/WNL.0b013e31820f2d79","article-title":"Use of ibuprofen and risk of Parkinson disease","volume":"76","author":"Gao","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2025.149738_b0250","unstructured":"Garwood, C.J., Ratcliffe, L.E., Morgan, S.V., Simpson, J.E., Owens, H.A., Villasenor, I.V., Heath, P.R., Romero, I.A., Ince, P.G., Wharton, S.B., 2018. Insulin and IGF 1 signalling pathways in human astrocytes in vitro and in vivo; characterisation , subcellular localisation and modulation of thereceptors. Vol., eds."},{"key":"10.1016\/j.brainres.2025.149738_b0255","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/13543784.2020.1764534","article-title":"Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease","volume":"29","author":"Glotfelty","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.brainres.2025.149738_b0260","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fphar.2020.00356","article-title":"Modeling Parkinson's Disease With the Alpha-Synuclein Protein","volume":"11","author":"G\u00f3mez-Benito","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.brainres.2025.149738_b0265","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094508","article-title":"Pathophysiological features of nigral dopaminergic neurons in animal models of Parkinson's Disease","volume":"23","author":"Guatteo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0270","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrm.2017.89","article-title":"Biochemical and cellular properties of insulin receptor signalling","volume":"19","author":"Haeusler","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.brainres.2025.149738_b0275","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson's disease and parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am. J. Med."},{"key":"10.1016\/j.brainres.2025.149738_b0280","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1212\/01.wnl.0000191154.78131.f6","article-title":"Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways","volume":"65","author":"Hilker","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2025.149738_b0285","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models","volume":"136","author":"H\u00f6lscher","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2025.149738_b0290","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/cells9030740","article-title":"Insulin resistance promotes Parkinson\u2019s disease through aberrant expression of \u03b1-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling","volume":"9","author":"Hong","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.brainres.2025.149738_b0295","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/(SICI)1096-9136(199712)14:12<1044::AID-DIA508>3.0.CO;2-F","article-title":"Insulin receptors are widely distributed in human brain and bind human and porcine insulin with equal affinity","volume":"14","author":"Hopkins","year":"1997","journal-title":"Diabet. Med."},{"key":"10.1016\/j.brainres.2025.149738_b0300","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1073\/pnas.1610371113","article-title":"Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson\u2019s disease","volume":"113","author":"Horvath","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0305","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson's disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.brainres.2025.149738_b0310","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.7150\/ijbs.27173","article-title":"The PI3K\/AKT pathway in obesity and type 2 diabetes","volume":"14","author":"Huang","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0315","article-title":"Role of exendin-4 in brain insulin resistance, mitochondrial function, and neurite outgrowth in neurons under palmitic acid-induced oxidative stress","volume":"10","author":"Jo","year":"2021","journal-title":"Antioxidants (basel)"},{"key":"10.1016\/j.brainres.2025.149738_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 Receptor agonists: a new treatment in Parkinson's disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0325","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1371\/journal.pbio.0060254","article-title":"Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism","volume":"6","author":"Kappeler","year":"2008","journal-title":"PLoS Biol."},{"key":"10.1016\/j.brainres.2025.149738_b0330","first-page":"972","article-title":"The insulin receptor and its cellular targets","volume":"86","author":"Kido","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.brainres.2025.149738_b0335","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease","volume":"202","author":"Kim","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.brainres.2025.149738_b0340","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008888","article-title":"Genetics of Parkinson\u2019s disease","volume":"2","author":"Klein","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.brainres.2025.149738_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.brainres.2025.149738_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2021.100914","article-title":"Diabetes, insulin and new therapeutic strategies for Parkinson\u2019s disease: Focus on glucagon-like peptide-1 receptor agonists","volume":"62","author":"Labandeira","year":"2021","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.brainres.2025.149738_b0355","article-title":"Severity of depressive and motor symptoms impacts quality of life in Parkinson\u2019s disease patients at an academic movement clinic: a cross-sectional study","volume":"8","author":"Lacy","year":"2023","journal-title":"Clinical Parkinson. Relat. Disord."},{"key":"10.1016\/j.brainres.2025.149738_b0360","unstructured":"Latif, W., Lambrinos, K.J., Rodriguez, R., 2021. Compare and contrast the glucagon-like peptide-1 receptor agonists (Glp1ras)."},{"key":"10.1016\/j.brainres.2025.149738_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101255","article-title":"Understanding insulin and its receptor from their three-dimensional structures","volume":"52","author":"Lawrence","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.brainres.2025.149738_b0370","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/brain\/awac309","article-title":"Cerebrovascular insulin receptors are defective in Alzheimer\u2019s disease","volume":"146","author":"Leclerc","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.brainres.2025.149738_b0375","doi-asserted-by":"crossref","first-page":"18543","DOI":"10.1074\/jbc.M414112200","article-title":"Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway","volume":"280","author":"Lee","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainres.2025.149738_b0380","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0006-8993(00)02573-7","article-title":"Glucose-regulated dopamine release from substantia nigra neurons","volume":"874","author":"Levin","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.brainres.2025.149738_b0385","article-title":"Actions of metformin in the brain: a new perspective of metformin treatments in related neurological disorders","volume":"23","author":"Li","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0390","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0395","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3390\/cells8070712","article-title":"Mitophagy in Parkinson\u2019s disease: from pathogenesis to treatment","volume":"8","author":"Liu","year":"2019","journal-title":"Cells."},{"key":"10.1016\/j.brainres.2025.149738_b0400","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.4103\/NRR.NRR-D-24-00568","article-title":"PI3K\/AKT signaling and neuroprotection in ischemic stroke: molecular mechanisms and therapeutic perspectives","volume":"20","author":"Liu","year":"2025","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.brainres.2025.149738_b0405","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson\u2019s disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainres.2025.149738_b0410","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1462240","article-title":"Neuroprotective effects of GLP-1 class drugs in Parkinson's disease","volume":"15","author":"Lv","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.brainres.2025.149738_b0415","doi-asserted-by":"crossref","first-page":"e2231","DOI":"10.1002\/brb3.2231","article-title":"The GLP-1\/GIP dual-receptor agonist DA5-CH inhibits the NF-\u03baB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01","volume":"11","author":"Lv","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.brainres.2025.149738_b0420","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12640-012-9330-y","article-title":"Reciprocal induction between \u03b1-synuclein and \u03b2-amyloid in adult rat neurons","volume":"23","author":"Majd","year":"2013","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.brainres.2025.149738_b0425","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1523\/JNEUROSCI.3928-08.2008","article-title":"RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation\/activation","volume":"28","author":"Malagelada","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2025.149738_b0430","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40120-018-0091-2","article-title":"Parkinson's Disease, the dopaminergic neuron and gammahydroxybutyrate","volume":"7","author":"Mamelak","year":"2018","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.brainres.2025.149738_b0435","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.2040-1124.2012.00196.x","article-title":"Glucose\u2010dependent insulinotropic polypeptide signaling in pancreatic \u03b2\u2010cells and adipocytes","volume":"3","author":"McIntosh","year":"2012","journal-title":"J. Diabet. Investigat."},{"key":"10.1016\/j.brainres.2025.149738_b0440","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson\u2019s disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.brainres.2025.149738_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101234","article-title":"The brain as an insulin-sensitive metabolic organ","volume":"52","author":"Milstein","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.brainres.2025.149738_b0450","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/mds.27492","article-title":"Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2025.149738_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10048-007-0116-y","article-title":"Towards a pathway definition of Parkinson\u2019s disease: a complex disorder with links to cancer, diabetes and inflammation","volume":"9","author":"Moran","year":"2008","journal-title":"Neurogenetics"},{"key":"10.1016\/j.brainres.2025.149738_b0460","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00313602","article-title":"Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease","volume":"87","author":"Moroo","year":"1994","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.brainres.2025.149738_b0465","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.molmed.2015.04.005","article-title":"Type 2 diabetes as a protein misfolding disease","volume":"21","author":"Mukherjee","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.brainres.2025.149738_b0470","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.brainres.2025.149738_b0475","article-title":"GLP\u20101 receptor agonists for Parkinson's disease","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.brainres.2025.149738_b0480","article-title":"GLP-1 receptor agonists for Parkinson's disease","volume":"7","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.brainres.2025.149738_b0485","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.2337\/diabetes.53.suppl_3.S190","article-title":"Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes","volume":"53","author":"Nauck","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.brainres.2025.149738_b0490","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","article-title":"Incretin and insulin signaling as novel therapeutic targets for Alzheimer\u2019s and Parkinson\u2019s disease","volume":"28","author":"Nowell","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.brainres.2025.149738_b0495","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010026","article-title":"Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling","volume":"19","author":"Oh","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0500","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/acn3.51343","article-title":"Effect of diabetes control status on the progression of Parkinson's disease: a prospective study","volume":"8","author":"Ou","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.brainres.2025.149738_b0505","doi-asserted-by":"crossref","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","article-title":"Diabetes mellitus and Parkinson disease","volume":"90","author":"Pagano","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2025.149738_b0510","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cells9071687","article-title":"Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications","volume":"9","author":"Pajares","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.brainres.2025.149738_b0515","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.acra.2015.07.014","article-title":"Diabetes, gray matter loss, and cognition in the setting of Parkinson disease","volume":"23","author":"Petrou","year":"2016","journal-title":"Acad. Radiol."},{"key":"10.1016\/j.brainres.2025.149738_b0520","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126403","article-title":"Role of Insulin in Health and Disease: an Update","volume":"22","author":"Rahman","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0525","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s11010-022-04587-x","article-title":"Impairment of insulin signaling pathway PI3K\/Akt\/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review","volume":"478","author":"Ramasubbu","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.brainres.2025.149738_b0530","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8936865","article-title":"GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"2021","author":"Rezaei","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.brainres.2025.149738_b0535","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/dc19-0760","article-title":"Association between glycemic status and the risk of Parkinson disease: a nationwide population-based study","volume":"43","author":"Rhee","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.brainres.2025.149738_b0540","doi-asserted-by":"crossref","DOI":"10.3390\/nu15163585","article-title":"The molecular mechanisms of the relationship between insulin resistance and Parkinson's disease pathogenesis","volume":"15","author":"Ruiz-Pozo","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.brainres.2025.149738_b0545","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molmet.2013.10.004","article-title":"Irs2 and Irs4 synergize in non-LepRb neurons to control energy balance and glucose homeostasis","volume":"3","author":"Sadagurski","year":"2014","journal-title":"Mol. Metab."},{"key":"10.1016\/j.brainres.2025.149738_b0550","doi-asserted-by":"crossref","unstructured":"Salcedo-Tello, P., Ortiz-Matamoros, A., Arias, C., 2011. GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration. Int. J. Alzheim. Dis. 2011.","DOI":"10.4061\/2011\/189728"},{"key":"10.1016\/j.brainres.2025.149738_b0555","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142241","article-title":"Insulin signaling in health and disease","volume":"131","author":"Saltiel","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.brainres.2025.149738_b0560","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.molmed.2013.01.002","article-title":"Shared dysregulated pathways lead to Parkinson's disease and diabetes","volume":"19","author":"Santiago","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.brainres.2025.149738_b0565","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1460-9568.2009.06657.x","article-title":"PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease","volume":"29","author":"Schintu","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.brainres.2025.149738_b0570","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: Similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.brainres.2025.149738_b0575","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neulet.2017.12.049","article-title":"Elevated nuclear phosphatase and tensin homolog (PTEN) and altered insulin signaling in substantia nigral region of patients with Parkinson\u2019s disease","volume":"666","author":"Sekar","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.brainres.2025.149738_b0580","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gendis.2019.01.004","article-title":"Impact of gene mutation in the development of Parkinson's disease","volume":"6","author":"Selvaraj","year":"2019","journal-title":"Genes Diseas."},{"key":"10.1016\/j.brainres.2025.149738_b0585","article-title":"Alpha-Synuclein Aggregation in Parkinson's Disease","volume":"8","author":"Srinivasan","year":"2021","journal-title":"Front Med (lausanne)."},{"key":"10.1016\/j.brainres.2025.149738_b0590","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1073\/pnas.1014715108","article-title":"Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage","volume":"108","author":"Stoica","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.brainres.2025.149738_b0595","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0304-3940(96)12357-0","article-title":"Insulin receptor mRNA in the substantia nigra in Parkinson's disease","volume":"204","author":"Takahashi","year":"1996","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.brainres.2025.149738_b0600","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.brainres.2025.149738_b0605","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1182803","article-title":"Integrated transcriptome and metabolome analysis to investigate the mechanism of intranasal insulin treatment in a rat model of vascular dementia","volume":"14","author":"Tang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.brainres.2025.149738_b0610","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1093\/hmg\/ddm159","article-title":"Parkinson's disease","volume":"16","author":"Thomas","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2025.149738_b0615","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s12640-021-00375-5","article-title":"Novel Pharmacotherapies in Parkinson\u2019s Disease","volume":"39","author":"Tizabi","year":"2021","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.brainres.2025.149738_b0620","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson's disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"The Lancet Neurology."},{"key":"10.1016\/j.brainres.2025.149738_b0625","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.901559","article-title":"Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K\/AKT\/mTOR Signaling Pathway","volume":"13","author":"Tong","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.brainres.2025.149738_b0630","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3233\/JAD-2009-0995","article-title":"Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity","volume":"16","author":"Tong","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.brainres.2025.149738_b0635","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/14737175.2017.1246183","article-title":"Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology","volume":"17","author":"Tramutola","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.brainres.2025.149738_b0640","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson's disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.brainres.2025.149738_b0645","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0306-4522(91)90049-T","article-title":"Immunohistochemical localization of insulin receptors and phosphotyrosine in the brainstem of the adult rat","volume":"42","author":"Unger","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainres.2025.149738_b0650","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","article-title":"Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort","volume":"18","author":"Wahlqvist","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.brainres.2025.149738_b0655","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.expneurol.2013.11.001","article-title":"Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice","volume":"251","author":"Wang","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainres.2025.149738_b0660","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010065","article-title":"GLP1 Receptor Agonists-Effects beyond Obesity and Diabetes","volume":"13","author":"Wilbon","year":"2023","journal-title":"Cells."},{"key":"10.1016\/j.brainres.2025.149738_b0665","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000417536","article-title":"The glycemic index","volume":"62","author":"Wolever","year":"1990","journal-title":"World Rev. Nutr. Diet."},{"key":"10.1016\/j.brainres.2025.149738_b0670","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/abbs\/gmz073","article-title":"High-fat diet causes increased endogenous neurotoxins and phenotype of Parkinson\u2019s disease in mice","volume":"51","author":"Wu","year":"2019","journal-title":"Acta Biochim. Biophy. Sin."},{"key":"10.1016\/j.brainres.2025.149738_b0675","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10495-007-0065-9","article-title":"Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt\/GSK-3beta\/caspase-3 mediated signaling pathway","volume":"12","author":"Wu","year":"2007","journal-title":"Apoptosis"},{"key":"10.1016\/j.brainres.2025.149738_b0680","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fnins.2018.00073","article-title":"The Role of Insulin\/IGF-1\/PI3K\/Akt\/GSK3\u03b2 Signaling in Parkinson's Disease Dementia","volume":"12","author":"Yang","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.149738_b0685","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.drudis.2018.08.005","article-title":"Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys","volume":"24","author":"Yaribeygi","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.brainres.2025.149738_b0690","doi-asserted-by":"crossref","first-page":"e3549","DOI":"10.1097\/MD.0000000000003549","article-title":"Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies","volume":"95","author":"Yue","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.brainres.2025.149738_b0695","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.4103\/1673-5374.303045","article-title":"Glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model","volume":"16","author":"Zhang","year":"2021","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.brainres.2025.149738_b0700","doi-asserted-by":"crossref","first-page":"33032","DOI":"10.1021\/acsnano.4c05693","article-title":"Multi Targeted Therapy for Alzheimer\u2019s Disease by Guanidinium-Modified Calixarene and Cyclodextrin Co-Assembly Loaded with Insulin","volume":"18","author":"Zhang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.brainres.2025.149738_b0705","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (lausanne)."},{"key":"10.1016\/j.brainres.2025.149738_b0710","first-page":"48","article-title":"TGF-beta1 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in Parkinson's disease models and patients","volume":"11","author":"Zhuo","year":"2024","journal-title":"Mil. Med. Res."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899325002987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899325002987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:41:29Z","timestamp":1783168889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899325002987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":142,"alternative-id":["S0006899325002987"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2025.149738","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parkinson\u2019s disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2025.149738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149738"}}